Which proton pump inhibitors (PPIs) are recommended for children with gastro‑esophageal reflux disease, and what are the appropriate dosing regimens?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended PPIs for Children

For children ≥1 year with documented GERD, omeprazole (0.7-3.3 mg/kg/day), lansoprazole (0.7-3 mg/kg/day), or esomeprazole (0.7-3.3 mg/kg/day) are the FDA-approved first-line PPIs; for adolescents 12-17 years, rabeprazole 20 mg daily is also approved. 1

Age-Specific PPI Recommendations

Infants (<1 year)

  • PPIs are NOT recommended for typical infant reflux or irritability 1
  • Placebo-controlled trials show PPIs provide no benefit over placebo for reducing crying/fussiness in infants 1, 2
  • PPIs may increase risk of lower respiratory tract infections, gastroenteritis, and necrotizing enterocolitis in this age group 1
  • Exception: Consider only if documented erosive esophagitis on endoscopy, despite the limited FDA approval

Children 1-11 Years

FDA-approved options with dosing:

  • Omeprazole: 0.7-3.3 mg/kg/day (ages 2-16 years)

    • Capsule contents can be sprinkled on soft foods
    • Effective dosage range demonstrated in clinical trials 1
  • Lansoprazole: 0.7-3 mg/kg/day (ages 1-17 years)

    • Multiple formulations: sprinkle capsules, strawberry-flavored disintegrating tablets
    • Can be administered via nasogastric tube in juice 1
    • Healed all cases of erosive esophagitis in 1-12 year olds in trials 1
  • Esomeprazole: 0.7-3.3 mg/kg/day (ages 1-17 years)

    • Sprinkle capsule contents on soft foods or administer in juice via NG tube 1

Adolescents 12-17 Years

All above options PLUS:

  • Rabeprazole: 20 mg daily (oral tablet) 1
    • Studies show similar symptom improvement at 0.5 mg/kg and 1 mg/kg doses 2

Critical Prescribing Principles

When to Use PPIs

Appropriate indications:

  • Documented erosive esophagitis on endoscopy
  • Symptomatic GERD unresponsive to lifestyle modifications
  • Esophagitis refractory to H2-receptor antagonists 1
  • Eosinophilic esophagitis (considered standard of care) 3

Inappropriate indications (avoid):

  • Uncomplicated infant regurgitation
  • Nonspecific irritability in infants
  • Without objective diagnostic confirmation in older children 1, 4

Formulation Selection by Age

  • Ages 1-5 years: Prefer sprinkle formulations (omeprazole, lansoprazole, esomeprazole) mixed with soft foods
  • Ages 6-11 years: Sprinkle formulations or disintegrating tablets (lansoprazole)
  • Ages ≥12 years: Standard tablets acceptable; rabeprazole becomes an option 1

Safety Considerations and Monitoring

Known Adverse Effects

  • Common (up to 14%): Headaches, diarrhea, constipation, nausea 1
  • Serious concerns with prolonged use (>2.5 years):
    • Enterochromaffin cell hyperplasia (up to 50% of children) 1
    • Increased risk of community-acquired pneumonia
    • Gastroenteritis and candidemia
    • Potential bone fracture risk 3

Duration of Therapy

  • Initial trial: 4-8 weeks for symptom assessment 1
  • Maintenance: Use shortest effective duration
  • Reassess regularly for deprescribing opportunities 4
  • Long-term use (>11 years) documented in small numbers but requires careful risk-benefit analysis 1

Comparative Efficacy

PPIs vs H2-Receptor Antagonists:

  • PPIs superior for symptom relief and healing erosive esophagitis 1
  • H2RAs develop tachyphylaxis within 6 weeks, limiting long-term use 1
  • Consider H2RAs (ranitidine 5-10 mg/kg/day divided 2-3 times daily) for short-term use or step-down therapy 1, 5

Between PPIs:

  • No robust evidence favoring one PPI over another in children 2
  • Choice based on FDA approval for age, available formulations, and dosing convenience

Common Pitfalls to Avoid

  1. Overprescribing in infants: Most infant reflux is physiologic and self-limiting; PPIs provide no benefit and carry infection risks 1, 4

  2. Prescribing without objective diagnosis: Use endoscopy or pH monitoring to confirm GERD before initiating PPIs in unclear cases 5

  3. Indefinite continuation: Establish planned reassessment and step-down strategy at initiation 4

  4. Ignoring weight-based dosing: Children require higher mg/kg doses than adults due to greater hepatic metabolic capacity 6

  5. Wrong formulation for age: Ensure age-appropriate formulation for medication adherence 1

Not FDA-Approved for Pediatrics

  • Pantoprazole: No pediatric indication (adult dose 40 mg daily only) 1
  • Dexlansoprazole: No pediatric indication 1

These should be avoided unless all approved options have failed and specialist consultation obtained.

Related Questions

What is the safest antacid for children, and what are the appropriate pediatric dosing guidelines?
Are proton pump inhibitors (PPIs) approved for use in a 15‑year‑old adolescent?
What is the recommended proton pump inhibitor (PPI) dosing and duration for a 13-year-old child with gastro‑esophageal reflux disease, including erosive esophagitis?
What over‑the‑counter medications are appropriate for an 8‑year‑old child with gastritis?
Is it safe to give Gaviscon (alginic acid antacid) to a 9-year-old child, and what is the appropriate dosage and duration?
Is oral minoxidil 2.5 mg recommended for treating androgenic alopecia in adults?
Does discontinuing latuda (lurasidone) cause an elevated white blood cell count?
In a 30-year-old Black male (6'5", 320 lb) with high‑titer speckled antinuclear antibody, markedly elevated ribonucleoprotein antibodies, proximal muscle weakness, elevated creatine kinase, normal cardiac evaluation, and glucose‑6‑phosphate dehydrogenase deficiency, what is the most likely diagnosis, what EMG findings are expected, is the myositis inflammatory or necrotizing, what is the prognosis, and how common is this condition in men?
How can I differentiate restless‑legs syndrome (RLS) pain from pain due to other causes?
In a 30‑year‑old Black male (6′5″, 320 lb) with hypertension treated with amlodipine, on a GLP‑1 receptor agonist for weight loss, G6PD deficiency, persistently positive antinuclear antibody with high‑titer anti‑RNP antibodies (speckled pattern), modestly elevated creatine kinase, proximal muscle weakness of shoulders, arms, hips, thighs and back, normal cardiac work‑up except low‑grade troponin elevations, what is the most likely diagnosis, what EMG findings should be expected, is a muscle biopsy indicated, and what is the prognosis?
What are the gastrointestinal manifestations of small-vessel vasculitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.